nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylscopolamine bromide—CHRM5—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.034	0.0342	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.029	0.0292	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0282	0.0283	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0263	0.0264	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0244	0.0245	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.024	0.0241	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0239	0.024	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0237	0.0238	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0237	0.0238	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0221	0.0222	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0204	0.0205	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0204	0.0205	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0202	0.0203	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0198	0.0199	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0198	0.0199	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0196	0.0197	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0185	0.0186	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0184	0.0185	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0184	0.0185	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0182	0.0183	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0172	0.0173	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0171	0.0172	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.017	0.0171	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0167	0.0168	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0166	0.0167	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0165	0.0166	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0155	0.0156	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0155	0.0156	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0155	0.0155	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0153	0.0154	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0129	0.013	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0129	0.013	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0128	0.0128	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0109	0.0109	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0108	0.0109	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0107	0.0108	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00905	0.0091	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00896	0.00901	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00879	0.00883	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.0087	0.00875	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00573	0.00576	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00568	0.00571	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0056	0.00563	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00544	0.00547	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00507	0.00509	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00482	0.00484	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.0048	0.00483	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00468	0.0047	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00466	0.00468	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00459	0.00461	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00436	0.00438	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00434	0.00436	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.0042	0.00422	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00411	0.00413	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00407	0.00409	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00394	0.00397	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00393	0.00395	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00389	0.00391	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00383	0.00385	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00382	0.00384	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00379	0.00381	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00378	0.0038	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00369	0.00371	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00365	0.00367	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00357	0.00359	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00356	0.00357	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00355	0.00357	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00355	0.00357	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00352	0.00354	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00338	0.0034	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00337	0.00339	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00334	0.00335	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00331	0.00332	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00328	0.0033	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00327	0.00329	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00324	0.00326	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00323	0.00325	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00322	0.00324	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00306	0.00307	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00305	0.00306	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00304	0.00306	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00302	0.00303	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00289	0.00291	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00288	0.0029	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00257	0.00259	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00257	0.00258	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00254	0.00255	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.0025	0.00251	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.0025	0.00251	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00249	0.0025	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00249	0.0025	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00247	0.00248	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00247	0.00248	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—HDC—Gilles de la Tourette syndrome	0.00246	0.00247	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00233	0.00234	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00232	0.00233	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00231	0.00233	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.0023	0.00231	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00214	0.00215	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00213	0.00215	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00211	0.00212	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00207	0.00208	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00201	0.00202	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00188	0.00189	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00187	0.00188	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00182	0.00183	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.0017	0.00171	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00163	0.00164	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00162	0.00163	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00161	0.00162	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00145	0.00146	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00145	0.00146	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00144	0.00144	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00141	0.00142	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00141	0.00141	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00139	0.0014	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00132	0.00133	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00132	0.00132	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00132	0.00132	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00131	0.00132	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00131	0.00132	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.0013	0.00131	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.0013	0.00131	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00128	0.00129	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00128	0.00128	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00127	0.00127	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00119	0.0012	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00119	0.0012	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00119	0.00119	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00118	0.00119	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00111	0.00111	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00108	0.00108	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.001	0.00101	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000921	0.000926	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000918	0.000923	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000909	0.000914	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000836	0.000841	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000834	0.000838	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000826	0.00083	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00078	0.000784	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000778	0.000782	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00077	0.000774	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000757	0.000761	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000755	0.000759	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000748	0.000752	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000706	0.000709	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000703	0.000707	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000702	0.000706	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000696	0.0007	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—nervous system—Gilles de la Tourette syndrome	0.000683	0.128	CbGeAlD
Methylscopolamine bromide—CHRM5—central nervous system—Gilles de la Tourette syndrome	0.000657	0.123	CbGeAlD
Methylscopolamine bromide—CHRM5—brain—Gilles de la Tourette syndrome	0.000522	0.0976	CbGeAlD
Methylscopolamine bromide—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000494	0.000497	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000493	0.000495	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000488	0.00049	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—nervous system—Gilles de la Tourette syndrome	0.000468	0.0877	CbGeAlD
Methylscopolamine bromide—CHRM2—central nervous system—Gilles de la Tourette syndrome	0.000451	0.0844	CbGeAlD
Methylscopolamine bromide—CHRM1—nervous system—Gilles de la Tourette syndrome	0.000426	0.0798	CbGeAlD
Methylscopolamine bromide—CHRM1—central nervous system—Gilles de la Tourette syndrome	0.000411	0.0768	CbGeAlD
Methylscopolamine bromide—CHRM3—nervous system—Gilles de la Tourette syndrome	0.000382	0.0714	CbGeAlD
Methylscopolamine bromide—CHRM3—central nervous system—Gilles de la Tourette syndrome	0.000367	0.0688	CbGeAlD
Methylscopolamine bromide—CHRM2—brain—Gilles de la Tourette syndrome	0.000358	0.067	CbGeAlD
Methylscopolamine bromide—CHRM1—brain—Gilles de la Tourette syndrome	0.000326	0.061	CbGeAlD
Methylscopolamine bromide—CHRM3—brain—Gilles de la Tourette syndrome	0.000292	0.0546	CbGeAlD
